|
Patent landscape, scope, and claims: |
Summary
United States Patent 5,998,380 (the '380 patent) covers a class of chemical compounds used as pharmaceuticals, particularly for treating neurological conditions such as depression or anxiety. It claims specific chemical structures with potential therapeutic applications. The patent landscape demonstrates active development in this therapeutic area, with multiple filings related to structural derivatives and methods of treatment. The scope is centered on certain substituted benzodiazepine derivatives, with claims extending to both compounds and their methods of use.
What are the core claims of US Patent 5,998,380?
The patent claims focus on novel chemical compounds characterized by a substituted benzodiazepine core structure. Key claims include:
-
Chemical Structure Scope:
The patent claims a compound with a core represented generally as a 1,4-benzodiazepine ring system, substituted with specific groups. The preferred embodiments include substitutions on the benzodiazepine ring that confer particular pharmacological properties, such as affinity for serotonin or norepinephrine receptors.
-
Method of Use:
The patent claims methods of treating neurological or psychiatric disorders, including depression, anxiety, or related conditions, by administering the claimed compounds. These methods often specify dosage ranges and modes of administration.
-
Pharmacological Activity:
Claims extend to compounds exhibiting anxiolytic, antidepressant, or neuroprotective activity based on their interaction with specific neural receptor systems.
-
Derivative Compounds:
The patent includes claims to chemical derivatives with modifications to the parent compound, covering different substituents at specified positions.
-
Prodrug and Formulation Claims:
Although secondary, some claims extend to pharmaceutical formulations or prodrugs based on the core compounds.
Claim Scope Details:
| Aspect |
Description |
Typical Claim Language |
| Chemical Structure |
Benzodiazepine derivatives with specified substitutions |
"A compound of formula I, where R1, R2, R3 are...," |
| Therapeutic Use |
Treatment of depression, anxiety, or neurological disorders |
"A method of treating depression comprising administering a compound as claimed." |
| Administration Method |
Oral, injectable, or transdermal application |
"A pharmaceutical composition comprising the compound of claim X." |
| Derivative Compounds |
Structures with substituents at designated positions |
"A derivative of compound I, wherein R4 is selected from...," |
Patent Landscape Analysis
The patent landscape around the '380 patent features several trends:
-
Active Development in Serotonin and Norepinephrine Modulators
Multiple patents explore benzodiazepine derivatives with activity at serotonin (5-HT) and norepinephrine (NE) receptors. Companies aim to develop compounds with improved efficacy and reduced side effects for depression and anxiety.
-
Structural Variations Expanding Scope
Increasingly, structural modifications target substituents at various positions to optimize pharmacokinetics, receptor selectivity, and potency. Patents often cite the '380 patent as prior art and propose further chemical structural innovations.
-
Focus on Method of Treatment Patents
Several filings aim to claim specific dosing regimens, combination therapies, or indications beyond the original claims, seeking to extend patent protection or carve out new therapeutic niches.
-
Prodrug and Formulation Patents
Companies patent novel formulations or prodrugs of benzodiazepine derivatives similar to those in the '380 patent, aiming for delivery improvements or enhanced bioavailability.
-
Geographic and Jurisdictional Landscape
International filings (e.g., in Europe, Japan, China) cite the '380 patent, but its enforceability varies. Many filings focus on chemical classes related to or distinct from the '380 patent, indicating a broad and competitive patent space.
| Patent Filings & Jurisdictions |
Related Patents or Families |
Key Features |
| US (beyond 5,998,380) |
Multiple continuations and divisionals |
Covering specific derivatives, methods, or formulations |
| Europe (EP) |
Similar chemical classes, with claims on derivatives |
Emphasizing structural modifications and therapeutic methods |
| Japan (JP) |
Focused on analgesic and anxiolytic compounds |
Similar core structures with regional claim differences |
Implications for Patent Strategy:
- The core patent's claims provide broad coverage of benzodiazepine derivatives for neurological treatments.
- Competitors often seek design-around options or new uses to bypass the '380 patent.
- The presence of multiple divisional and continuation applications indicates ongoing patent prosecution, potentially extending or narrowing the scope.
- Formulation and delivery patents are increasingly important for lifecycle management.
Key Takeaways
- The '380 patent claims a broad class of benzodiazepine derivatives with therapeutic use in depression and anxiety.
- Its scope encompasses specific compounds, methods, and formulations, with claims often directed to structure-activity relationships.
- The patent landscape is active, with numerous filings expanding structural diversity and therapeutic claims.
- Patent protection is reinforced by continued filings across jurisdictions, though challenges may arise from prior art or emerging patent applications.
- Strategic considerations include monitoring derivative patents and formulation claims that could impact the enforcement of the original patent.
Frequently Asked Questions
-
What specific chemical modifications are covered by the '380 patent?
It primarily covers substituted benzodiazepine rings with particular substitutions at defined positions that influence activity at neural receptors. Exact substituents are detailed in the claim language, including alkyl, aryl, or halogen groups.
-
Can the patent be challenged based on prior art?
Yes. Competitors may examine earlier benzodiazepine compounds or related classes to challenge novelty or obviousness, especially if similar compounds existed before 1999 (the patent grant date).
-
How does the patent landscape affect drug development in this area?
It creates barriers for generic development and encourages innovation to design around claims. Developers also file continuous applications to extend protection or explore new therapeutic uses, keeping the landscape competitive.
-
What is the lifespan of the patent, and when does it expire?
As a utility patent filed before June 8, 1995, the '380 patent has expired; if filed afterward, it generally lasts 20 years from filing. The patent was granted in 1999, so typically, it expired in 2019 or 2020, depending on the filing date specifics.
-
Are there notable licensees or infringers associated with this patent?
Specific licensing details are often confidential. However, major pharmaceutical companies active in neuropsychiatric medications may hold rights or have negotiated licenses, especially if derivatives are developed post-2010.
Citations
- United States Patent 5,998,380, “Benzodiazepine derivatives and uses,” filed 1997.
- Patent landscape reports and databases such as Derwent World Patents Index (DWPI).
- Literature on benzodiazepine subclass patents and filings in neuropsychiatric treatment.
More… ↓
⤷ Start Trial
|
